Enhancing Treg persistence by inhibiting necroptosis restrains autoimmune pathology
Journal of Clinical Investigation · 02.11.2026 · 136 (21)
DOI: 10.1172/jci207077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 01.09.2026. Verfasst von Qiaoyan Wu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Necroptosis, Multiple Sclerosis, Lupus Erythematosus, Systemic. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China National Natural Science Foundation, Shanghai Key Laboratory of Aging Studies, CAS Pioneer Initiative.
Abstract (Originalsprache)
Regulatory T cells (Tregs) hold great promise as next-generation therapeutics for autoimmune diseases. However, maintaining their functional persistence within inflamed tissues remains a major translational challenge. Using an in vitro system that recapitulates the inflammatory CNS milieu of multiple sclerosis (MS), together with a pooled shRNA screen, we identify necroptotic signaling as a key driver of Treg death, thereby compromising Treg functional persistence under inflammatory conditions. We further demonstrate that Tregs in both a mouse model of MS and patients with MS exhibited a preferential susceptibility to receptor-interacting serine/threonine kinase 1–dependent (RIPK1-dependent) necroptosis. Mechanistically, a FOXP3-driven, low-glucose metabolic program rendered Tregs intrinsically susceptible to necroptosis by limiting O-GlcNAcylation (O-GlcNAc) modification on RIPK1. This vulnerability was not shared by conventional T cells under comparable inflammatory conditions. Finally, in combination with adoptive Treg transfer, we show that selective inhibition of necroptosis in Tregs enhanced their survival and suppressive function at sites of active inflammation, thereby reducing autoimmune pathology in mouse models of MS and systemic lupus erythematosus. Together, these findings identify necroptotic cell death as a barrier to Treg persistence within inflamed tissues and highlight the therapeutic potential of necroptosis-resistant Tregs for the treatment of autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Research Center on Biology and Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Department of Neurology, and.
- Department of Anesthesiology, Key Laboratory of the Ministry of Education, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Clinical Research Center, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Shanghai Key Laboratory of Aging Studies, Shanghai, China.
Förderung
- China National Natural Science Foundation
- Shanghai Key Laboratory of Aging Studies
- CAS Pioneer Initiative
Zitieren
APA
Wu, Q., Cui, N., Gao, L., Lu, Z., Ao, X., Pang, R., Li, X., Pan, H., Xu, D., Li, P., Yuan, J., & Zou, C. (2026). Enhancing Treg persistence by inhibiting necroptosis restrains autoimmune pathology. Journal of Clinical Investigation, 136(21). https://doi.org/10.1172/jci207077
Vancouver
Wu Q, Cui N, Gao L, Lu Z, Ao X, Pang R, et al. Enhancing Treg persistence by inhibiting necroptosis restrains autoimmune pathology. Journal of Clinical Investigation. 2026;136(21). doi:10.1172/jci207077
BibTeX
@article{Wu2026,
author = {Wu, Qiaoyan and Cui, Na and Gao, Li and Lu, Zhihui and Ao, Xiang and Pang, Rui and Li, Xingyan and Pan, Heling and Xu, Daichao and Li, Peiying and Yuan, Junying and Zou, Chengyu},
title = {Enhancing Treg persistence by inhibiting necroptosis restrains autoimmune pathology},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {21},
doi = {10.1172/jci207077}
}
EUVIMED